Pembrolizumab adjuvant therapy trial for hepatocellular carcinoma recurrence-free survival

This is a Phase 3 randomized controlled trial (clinical trial protocol) evaluating adjuvant pembrolizumab versus placebo in 959 participants with hepatocellular carcinoma (HCC) who achieved a complete radiological response after surgical resection or local ablation. The primary outcomes are recurrence-free survival (RFS) and overall survival (OS), with a follow-up of 69.7 months.

The intervention is pembrolizumab (a biological), and the comparator is placebo. The study is set in the adjuvant therapy setting. However, the main results for RFS, OS, and all effect sizes are not reported; therefore, no numerical outcomes, p-values, or confidence intervals can be provided.

Safety and tolerability data, including adverse events, serious adverse events, and discontinuations, are not reported. The lead sponsor is Merck Sharp & Dohme LLC. Key limitations include the absence of reported results, which precludes assessment of efficacy or safety.

Practice relevance is not reported. While the randomized design supports causal inference, the lack of results means causality cannot be assessed from the provided text. Clinicians should await published outcomes before considering this regimen.